Licensing and Technology Transfer for Life Science and Tech CompaniesFebruary 21, 2017
Technology Transfer – A Journey From Invention to Startup
Abi Barrow. Director, Office of Technology Commercialization and Ventures, UMASS
Commercializing Academic Technology – Key Licensing Terms
Licensing and Technology Transfer for Life Science and Tech Companies
Lori Pressman, business development and technology transfer strategic advisor
Are you an inventor or entrepreneur seeking to license technology from a university or a research establishment?
Are you a technology owner seeking to license it out to existing companies to gain revenue? Or to develop, commercialize and market your products and create a new start-up company?
Our speakers will offer both perspectives discussing licensing technology from Institutions and research establishments. What are typical and atypical terms? What and how to negotiate? At what stage of development can we attract seed investment? How do we assess the commercialization and marketability? What unmet needs are met and how bad is the “pain”, i.e. maket size or a unique strategy? How to transition from the lab into viable and profitable products, i.e. “mind-to market” strategy? Typical terms and payment structures the entrepreneur or the Angel/Angel group, VC will seek in licensing will be discussed. What is royalty, fees and dividends? What are the license fees and milestones? What is the equity for the licensor? What are terms on sublicensing and royalty stacking?
Our speakers will also discuss licensing technology to a newly formed start-ups and early stage companies. They will also discuss licensing terms and offer insights – dos and don’ts – for entrepreneurs and start-up companies to successfully license technology from Institutions.
In addition, our speakers will also speak as a licensor, discussing how their institution/research establishment licenses out technology. Others discussions items will involve terms that a small or mid-size high tech company seek, as it licenses out its technology to generate revenue, as it acquires technology through cross-licensing, as it secures sources of supply, as it maximizes incentives to gain sales and market traction, and the implications of licensing on mergers and acquisitions.
Whether you are or want to be a technology licensor or licensee, there is much to learn from the experience of our speakers.
6:00 – 7:00 PM Registration & networking
7:00 – 7:10 PM ENET Chairman’s announcements
7:10 -7:25 PM E Minute – Up to 3 Startup companies presentations
7:25 -8:15 PM – 3 or 4 expert speakers on the night’s topic
8:15 -8:30 PM – Audience / Speakers Q & A
8:30 -9:00 PM – Final networking including meeting speakers
Venue: Pivotal Labs, 145 Broadway, 3rd Floor, Cambridge, MA
Parking: After 6:00 pm, the parking fee for Blue Garage next door is $10
Lori Pressman has been an independent deal maker, license negotiator, business development and technology transfer strategic advisor since 2000. Recent assignments include licensing biotech and oncology inventions for academic medical centers, and securing IP licenses for small companies in energy and instrumentation . She was a Director at Harris & Harris (NASDAQ:TINY) from 2002-2012, an advisor for Axsun Technologies prior to its acquisition by Volcano, and Assistant Director with signatory authority of the MIT Technology Licensing Office.
She is a member of the grant review committee at the MIT Deshpande Center for Technological Innovation and frequent coach of entrepreneurs and students studying entrepreneurship and business development. She is a reasonable royalty damages expert, a metrics guru for AUTM and BIO, and a member of the AUTM Public Policy Committee. She is an inventor on a half dozen medical device patents and earned the SB, Physics from MIT and the MSEE from the Columbia School of Engineering. Earlier in her career, she was a practicing engineer, working on optoelectronic materials and devices at Bell Laboratories and Lasertron, an MIT Lincoln Laboratory start-up.
Abi Barrow. Director, Office of Technology Commercialization and Ventures, UMASS firstname.lastname@example.org
Dr. Abigail Barrow is the Interim Executive Director, Office of Technology Commercialization and Ventures (OTCV) at the University of Massachusetts. She joined the UMass President’s Office in 2004 as the Founding Director of the Massachusetts Technology Transfer Center (MTTC) which is housed in OTCV. At OTCV she supports the campus technology transfer programs as well as assisting with start-up formation and other system wide entrepreneurship activities at UMass. She is also responsible for the overall management of the MTTC and the development of its programs. Prior to joining UMass, Dr. Barrow served as managing director of William J. von Liebig Center at the University of California San Diego (UCSD). The von Liebig Center was created in 2001 to support the commercialization of research being performed in the UCSD Jacobs School of Engineering.
Dr. Barrow worked in a variety of roles at UCSD CONNECT from 1990 to 2001. At CONNECT, she developed and expanded many of its programs to support early-stage company formation and technology commercialization. The CONNECT program is internationally recognized and has been successfully replicated in many other regions around the world.
Dr. Barrow is on the board and is Chair of Venture Well (formerly the National Collegiate Inventors and Innovators Alliance). Dr. Barrow received her Ph.D. from the Science Studies Unit and a B.Sc. in Mechanical Engineering from the University of Edinburgh.
Seema Basu, PhD, Market Sector Leader, Innovation , Partners Health Care
As Market Sector Leader, Seema Basu, PhD, directs the strategy for open innovation and strategic research collaborations. She leads a team responsible for managing and partnering portfolios from Orthopedics, Regenerative Medicine, Ragon Institute of MGH, MIT and Harvard, and MGH Center for Global Health. The team also manages strategic alliances and new initiatives, such as the Innovation Fellows Program for workforce development and collaboration with industry. She represents Partners at numerous national and regional organizations.
She has more than a decade of deep experience in IP & licensing at Partners and Harvard and a successful laboratory career at Parke-Davis and Albany Medical College. She earned her PhD from the University of Notre Dame.
Moderator and Organizer:
Dr. Nathalie Goletiani, MD, Founder & CEO, POWERFEM Therapeutics
Dr. Goletiani is the Founder and Chief Executive Officer of POWERFEM Therapeutics, a company devoted to novel, networked treatment methods for the care of those suffering from substance abuse and mental illness. Her extensive clinical research into the hormonal effects of nicotine, opioid and cocaine use lead her to new concepts and mechanisms in understanding and treating psychiatric disorders, in particular, disorders experienced by underserved female populations. At Harvard’s McLean Hospital, she was charged with rebuilding and responsible for all the operations of Clinical Research Program, including simultaneously running multiple clinical trials. Based on her patented work, she founded POWERFEM Therapeutics, an independent company devoted to creating new treatments and healthcare solutions. POWERFEM incorporates novel disease concepts and treatments to design cost-effective, integrated mental and substance abuse care solutions across multiple provider networks.
Dr. Goletiani has received numerous national and international awards including most recently the Harvard Livingston Award for the investigation of complex underlying mechanisms in the neurobiology of women. She also received a Harvard University Zinberg Fellowship specifically to support her research on alcohol and drug use disorders. Her research provides a valuable basis for psychotherapeutic public policy decision making on issues of substance abuse and the integrated treatment of mental illness. She has extensively published the results of her research in peer reviewed journals.
Nathalie completed basic and clinic fellowships at the Harvard School of Public Health and at Harvard Medical School. In addition, she has been trained at and conducted medical research at Tbilisi State Medical University, University of Amsterdam and King’s College in London.